Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.2437 EUR
−39.46 M EUR
2.56 M EUR
19.23 M
About Dianthus Therapeutics, Inc.
Sector
Industry
CEO
Marino Garcia
Website
Headquarters
New York
Founded
2015
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Dianthus Therapeutics, Inc. stocks are traded under the ticker A3ERZ4.
A3ERZ4 stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in Dianthus Therapeutics, Inc. price.
We've gathered analysts' opinions on Dianthus Therapeutics, Inc. future price: according to them, A3ERZ4 price has a max estimate of 79.99 EUR and a min estimate of 34.28 EUR. Watch A3ERZ4 chart and read a more detailed Dianthus Therapeutics, Inc. stock forecast: see what analysts think of Dianthus Therapeutics, Inc. and suggest that you do with its stocks.
A3ERZ4 stock is 0.00% volatile and has beta coefficient of 2.21. Track Dianthus Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Dianthus Therapeutics, Inc. there?
Yes, you can track Dianthus Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Dianthus Therapeutics, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
A3ERZ4 earnings for the last quarter are −0.66 EUR per share, whereas the estimation was −0.53 EUR resulting in a −24.45% surprise. The estimated earnings for the next quarter are −0.82 EUR per share. See more details about Dianthus Therapeutics, Inc. earnings.
Dianthus Therapeutics, Inc. revenue for the last quarter amounts to 1.95 M EUR, despite the estimated figure of 665.65 K EUR. In the next quarter, revenue is expected to reach 922.72 K EUR.
A3ERZ4 net income for the last quarter is −22.61 M EUR, while the quarter before that showed −16.44 M EUR of net income which accounts for −37.55% change. Track more Dianthus Therapeutics, Inc. financial stats to get the full picture.
No, A3ERZ4 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 53.00 employees. See our rating of the largest employees — is Dianthus Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Dianthus Therapeutics, Inc. EBITDA is −74.07 M EUR, and current EBITDA margin is −1.69 K%. See more stats in Dianthus Therapeutics, Inc. financial statements.
Like other stocks, A3ERZ4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Dianthus Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.